Development and validation of a sensitive ELISA for quantitation of Grastim® (rhG-CSF) in rat plasma: application to a pharmacokinetic study

Grastim® is bacterially produced recombinant counterpart of human granulocyte colony stimulating factor (G‐CSF). It has biological activity similar to that of endogenous G‐CSF. In the present work a sensitive, accurate, precise and enzyme‐linked immunosorbent assay (ELISA) for the quantitation of G‐CSF in rat plasma was developed and validated. The ELISA method employed a technique in which anti‐human‐G‐CSF was adsorbed onto 96‐well maxisorp plates and used to capture the G‐CSF in rat plasma samples. The captured G‐CSF was then detected using streptavidin‐HRP amplification system. Absolute recovery was >90% from rat plasma. The validation includes assessments of method accuracy and precision, range of reliable response, lower limit of quantitation (LLOQ), storage stability (30 days) in rat plasma and assay specificity. The standard curve for G‐CSF was linear (R2 > 0.996) in the concentration range 4.88–625 pg/mL. The LLOQ was established at 4.88 pg/mL. The inter‐ and intra‐day precisions in the measurement of quality control (QC) samples, 15, 250 and 500 pg/mL, were in the range 3.00–8.66% relative standard deviation (RSD) and 1.03–4.69% RSD, respectively. Accuracy in the measurement of QC samples was in the range 87.28–110.79% of the nominal values. The assay shows dilutional linearity and specificity. Stability of G‐CSF was established for 30 days at −80°C and through three freeze–thaw cycles. The validated assay was successfully employed for the assessment of pharmacokinetic disposition of G‐CSF in rats. Copyright © 2006 John Wiley & Sons, Ltd.